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Inferior vena cava resection and reconstruction for
retroperitoneal tumor excision
William Quinones-Baldrich, MD,a Ali Alktaifi, MD,a Fritz Eilber, MD,b and
Frederick Eilber, MD,b Los Angeles, Calif
Objective: This study reviews the results of en bloc resection of the inferior vena cava (IVC) for malignant tumor excision
and reconstruction.
Methods: A prospective database was reviewed. IVC resection was categorized as suprarenal, perirenal, infrarenal, or
extensive (>one segment resected). Repairs were divided into primary, patch, or circumferential. Tumor type, perioper-
ative morbidity, mortality, and graft patency were recorded.
Results: Between 1990 and 2011, 47 patients (21 women; mean age, 56; range, 35-89 years) underwent IVC resection for
en bloc tumor excision. Sarcomas were most common (36 [77%]: 30 primary IVC). Eleven patients had primary IVC
repair, nine patch repair (two autogenous), and 27 had circumferential replacement with a polytetrafluoroethylene ringed
graft. Extensive IVC reconstruction in 18 patients included the entire IVC, with renal (RV) and hepatic vein
reimplantation in eight; suprarenal and perirenal in six (seven RVs reimplanted); and infrarenal and perirenal in four
(four RVs reimplanted). Nine single-segment IVC replacements were infrarenal. Morbidity was 10.6%: one each with
bowel obstruction, chyle leak, renal failure with complete recovery (left RV reimplant, right nephrectomy), reoperation
for bleeding, and IVC graft thrombosis. Morbidity did not differ by type of reconstruction. There was no mortality.
Follow-up ranged from 1.5 to 216 months (18 years) with a mean of 3.5 years. Computed tomography or duplex scans
were available in 28 of 47 patients and in 15 of 27 patients in group 3 at a mean follow-up of 36 and 20 months,
respectively. One IVC graft thrombosis was documented at 10 months after chemotherapy/sepsis. Tumor recurrence
caused three graft stenoses. Cumulative 5-year patency in group 3 was 80% (imaging) and 92% (clinical). Lower extremity
edema was universally avoided. Cumulative 5-year survival for the series was 45%  8.5%. Mean long-term survival was
5.8 0.56 years (range, 4 months-17 years), with a significant difference between primary or patch (mean, 6.5 years) and
circumferential or extensive repair (mean, 4.2 years; P < .005). Cumulative (47% vs 52%) and mean (3.1 vs 3.6 years; P
> .12) survival was similar between patients with single-segment and extensive IVC resection and replacement.
Conclusions: IVC resection and reconstruction for en bloc tumor excision is safe, even when extensive repairs are necessary.
Replacement of the IVC with prosthetic graft avoids extremity venous complications and likely contributes to quality of
survival. Survival depends on tumor behavior and degree of IVC involvement, where primary and patch repair has a better
prognosis than circumferential resection. (J Vasc Surg 2012;55:1386-93.)
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mRetroperitoneal malignant tumors are most commonly
of renal origin or are sarcomas. Both can present with
involvement of the inferior vena cava (IVC). Renal cell
carcinomas that extend into the IVCmost often are limited
to tumor thrombus that is amenable to removal without
major IVC resection. Sarcomas on the other hand, can
invade the wall of the vena cava, with occasional tumor
thrombus extending cephalad, or can be primary, arising
from the cava itself. In these cases, en bloc surgical resection
of the tumor and vena cava is an essential component for
treatment because chemotherapy or radiotherapy alone are
ineffective.1
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1386Most patients with sarcomas with IVC involvement
resent with abdominal distention, abdominal discomfort,
palpable mass, or are asymptomatic. Occlusion or throm-
osis of the IVC secondary to tumor involvement is rare. In
ost instances, there is partial occlusion from a combina-
ion of tumor involvement and compression. Patients pre-
enting with lower extremity edema more often have deep
enous thrombosis (DVT).Whether completely or partially
ccluded, lower extremity edema on presentation is seen in
30% of patients because the slow-growing nature of most
f these malignancies2 permits the development of collat-
ral venous drainage.
The optimal management of the IVC after resection is
ontroversial, with some advocating ligation2,3 and others
elective4 or routine reconstruction.1,5,6 The rationale for
he latter is based on the need to resect these collateral
athways for complete tumor removal.
Our center reported the results of IVC replacement at
he time of retroperitoneal tumor resection in 1998.6 Be-
ause of this positive early experience, we have continued to
ecommend IVC reconstruction when en bloc IVC resec-
ion is necessary for complete retroperitoneal tumor re-
oval. This report is a review of a prospective database of all
atients who underwent partial or complete IVC resection
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neal tumor; specifically, morbidity, mortality, and survival
according to extent of IVC resection are reviewed. Surgical
technique for IVC reconstruction, type of tumor, cumula-
tive patency of IVC replacement, and clinical results are
presented.
METHODS
The protocol for this study was approved by the UCLA
Medical Center Internal Review Board.
Patients. A prospectively maintained database of pa-
tients with retroperitoneal tumors was queried to identify
patients who presented with involvement of the IVC.Med-
ical records were reviewed to select patients who underwent
attempted curative resection as determined by the surgical
team from preoperative imaging. Specifically, we excluded
patients who were deemed nonresectable due to metastatic
disease and those with renal cell carcinoma in which the
IVC involvement was limited to tumor thrombus, without
invasion of the caval wall.
Demographics recorded included age at presentation,
sex, and extent of the involvement of the IVC. Histologic
categorization of the tumor was noted as obtained preop-
eratively or at operation. Operative details included the
extent of IVC involvement, and based on anatomic land-
marks, was divided into a retrohepatic, suprarenal, perire-
nal, infrarenal, or extensive if more than one of these
segments was involved. Depending on the involved seg-
ment, renal or hepatic veins, or both, were reimplanted.
Management of IVC involvement was categorized in
three groups, according to the surgical repair necessary, as
resection with primary repair, resection with autologous or
prosthetic patch repair, or circumferential resection with
graft replacement. Primary repair was defined as resection
of a portion of the IVC with primary closure (group 1).
Patch closure was performed when a larger defect created
by the resection required patch repair to avoid narrowing
the IVC (group 2). Circumferential resection of the IVC
was managed with replacement using a prosthetic graft
(group 3).
Intraoperative complications were recorded. Details of
the postoperative course were collected and analyzed. Early
mortality was defined as death30 days or during the same
hospital admission. Follow-up was performed initially by
the vascular and surgical oncology services, with long-term
follow-up done primarily by the latter. Re-evaluation by the
vascular service was done at the request of the primary
physician or the oncology service based on clinical symp-
toms. Imaging was obtained if patients developed symp-
toms of venous hypertension such as lower extremity
edema, scrotal edema, or hematuria.
Patency of the IVC reconstruction was determined by
computed tomography (CT), duplex scan, or clinically.
Cumulative patency for group 3 was calculated from imag-
ing alone using the last study available and separately, on
clinical grounds.
Long-term survival was calculated using the Social Se-
curity Death Index (SSDI) so that patients lost to follow-up tor 1 year would be included. This index represents
ll-cause mortality; therefore, death was attributed to the
alignancy in all cases. Mean and cumulative survival was
alculated. Cumulative calculations were done by actuarial
ethods using XLStat 2011.4.02 software (Addinsoft
orp, New York, NY) and expressed  the standard error
ith a 5% confidence level.
Operative technique. Some of the technical aspects of
he IVC replacement during malignant tumor excision
ave been previously reported.7 Placement of the incision is
etermined by the location of the tumor. Inmost instances,
etroperitoneal and intraperitoneal exposure are both nec-
ssary. A midline incision is adequate for exposure of the
erirenal and infrarenal segment of the IVC. If the tumor
xtends laterally, however, a flank incision curving toward
he midline provides the best exposure. When the retrohe-
atic vena cava requires exposure, a right thoracoabdomi-
al incision is preferred.
Primary repair is performed when 50% narrowing of
he lumen will result; otherwise, a patch repair is used. If
owel resection is required as part of the tumor excision, an
utologous patch is chosen. We prefer using the internal
ugular vein for this purpose, avoiding vein harvest from the
ower extremities, which could increase the risk of venous
omplications. When circumferential replacement is neces-
ary, a ringed polytetrafluoroethylene (PTFE) graft that is
maller than the IVC is selected (typically, 12-14 mm) to
romote faster velocities through the graft segment. The
ings are maintained at openings used for reimplantation of
ig 1. Technique for reimplantation of renal vein onto ringed
olytetrafluorethylene graft. Note preservation of rings up to the
raft opening.he renal vein or hepatic veins (Fig 1).
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May 20121388 Quinones-Baldrich et alRight renal vein reimplantation is necessary due to the
lack of collateral venous outflow. Right renal artery control
is used routinely during right renal vein reimplantation to
avoid congestion of the organ. Left renal artery control
during the left renal vein reimplantation is used only when
the left gonadal and left adrenal vein have been ligated as
part of the resection. The reconstruction is performed from
the superior margin of the caval resection to inferior, allow-
ing earlier restoration of venous outflow to the renal veins
when the perirenal segment is involved.
Replacement of the retrohepatic segment of the IVC
requires inflow and outflow control (hepatic vascular isola-
tion). Inflow control is accomplished with a combination of
clamping of the infrahepatic vena cava and a Pringle ma-
neuver (hepatic artery and portal vein control). This can be
done with a soft vascular clamp of the hepatic triad, without
individual dissection of the hepatic artery and the portal
vein. Outflow control requires suprahepatic, infradiaphrag-
matic clamping of the vena cava. We have not found it
necessary to control the vena cava above the diaphragm in
our cases. The clamping sequence should first be the infra-
hepatic vena cava, followed by the portal vein and hepatic
artery control, and last, the suprahepatic portion of the vena
cava. If hypotension occurs during clamping, additional
volume is administered as needed. Ischemia time should be
kept 30 minutes, and flow should be re-established as
soon as the retrohepatic portion of the replacement is
completed. Proper planning and preparation of the graft to
limit hepatic ischemia time is critical. In our experience,
portal-to-venous bypass has not been necessary.
Intraoperative systemic anticoagulation is not used
routinely and should be avoided, particularly for large
tumor resections. The presence of thrombus (not tumor
thrombus), history of lower extremity DVT, or pulmonary
embolism is considered as an indication to use systemic
heparin during resection (intravenous heparin, 0.6-0.8
mg/kg). In the absence of these indications, we prefer
liberal use of heparinized saline (10 U/mL). The graft
“sweating” seen in arterial reconstructions with PTFE
grafts does not occur in these low-pressure venous repairs.
During unclamping, the patient is placed in Trendelen-
burg, a Valsalva maneuver is induced by the anesthesiolo-
gist, and the graft is filled with heparinized saline when
needed to avoid air embolism. Prosthetic reconstructions
are covered with surrounding tissue or an omental flap, or
both, to avoid contact with the intestines, particularly the
duodenum.
Pulsatile compression boots during the initial postop-
erative period and pressure stockings are used in all pa-
tients. All patients are prescribed aspirin after surgery.
RESULTS
Between 1990 and 2011, 58 patients were evaluated at
our institution for retroperitoneal tumors with potential
IVC involvement. All patients were managed by a team of
oncologic (F.E., F.E.) and vascular surgeons (W.Q-B.).
Five patients presented with renal cell carcinoma with IVC
involvement limited to tumor thrombus. At exploration, 1wo patients had no invasion of the IVC, and the tumor was
emoved without any caval resection, and four patients
ere unresectable because of involvement of multiple ad-
acent structures or regional extent of disease, as docu-
ented in the operative notes. These 11 patients were
xcluded from further analysis for the purposes of this
eview.
During a 21-year interval, 47 consecutive patients (26
en, 21 women) underwent surgical resection and recon-
truction of the IVC for en bloc malignant tumor excision.
atients were a mean age of 56 years (range, 35-89 years).
ll patients had preoperative CT scans or magnetic reso-
ance imaging, or both, for evaluation of the extent of the
alignancy and involvement of the IVC.
All patients had preoperative needle biopsy. The histo-
ogic type was confirmed by pathology of the entire speci-
en. There were 36 sarcomas, with 30 being primary of the
VC, three adrenal tumors, and two teratomas. The re-
aining six consisted of a Wilms tumor, a malignant pheo-
hromocytoma, a neuroendocrine carcinoma, a recurrent
ransitional cell carcinoma, a duodenal carcinoma, and a
etastatic seminoma. Tumor size averaged 11.6 cm
range, 1-36 cm) in length and 6.5 cm (range, 1-20 cm) in
iameter. Tumor margins of the resected portion of the
VC were all negative.
All patients received adjuvant chemotherapy or radio-
herapy, or both, preoperatively or postoperatively, or
oth. These adjuvant treatments varied throughout the
nterval of the experience. During the last 10 years, more
atients received preoperative treatment, particularly those
ith large tumors that were initially considered unresect-
ble by the referring physician.
Resection and primary repair of the IVC (group 1) was
erformed in 11 patients, of which seven were in the
nfrarenal segment, three in the perirenal segment, and one
he suprarenal segment, with nephrectomy in four, chole-
ystectomy in one, bilateral adrenalectomy in one, primary
epair of the aorta in two, celiac graft replacement in one,
nd renal artery reimplantation in one, all for tumor in-
olvement.
IVC resection with patch closure (group 2) was per-
ormed in nine patients (seven synthetic and two autoge-
ous venous patches), of whom five involved the infrarenal
egment and four the perirenal IVC. This group required
wo nephrectomies and one bifurcated aortic graft replace-
ent (for tumor involvement).
Twenty-seven patients underwent circumferential re-
ection of the IVC for en bloc tumor resection (group 3).
ighteen patients in this group had extensive involvement
f more than one segment of the IVC. Eight patients had
nvolvement of all four segments of the IVC, requiring
enal vein and hepatic vein reimplantation. Six patients had
uprarenal and perirenal involvement, with seven renal vein
eimplantations, and four were infrarenal and perirenal,
ith four renal vein reimplantations. The nine single-
egment graft replacements in this group were infrarenal.
TFE ring-reinforced prosthetic grafts, ranging from 12 to
6 mm (26 of 27, 12-14 mm), were used in all of these
h
h
b
t
w
l
w
n
m
p
w
v
i
2
m
N
g
t
t
t
p
a
b
y
c
S
(
d
r
r
c
n
i
ard e
JOURNAL OF VASCULAR SURGERY
Volume 55, Number 5 Quinones-Baldrich et al 1389patients except one. The latter was a patient with infrarenal
vena cava thrombosis requiring resection of the infrarenal
and suprarenal IVC, right nephrectomy, and a 10-mm ring
reinforced PTFE graft from the left renal vein to the infra-
hepatic vena cava. This patient was given intraoperative
systemic heparin based on the presence of infrarenal IVC
thrombosis. Three additional patients were systemically
heparinized during surgery for history of DVT (two in
group 3), or pulmonary embolism (one in group 1).
The mean hospital stay for all groups was 9 days (range,
5-19 days), with no significant difference among the three
groups. Estimated mean blood loss was 1000 mL (range,
80-3700 mL), with no significant difference among group
1 (1100 mL), group 2 (620 mL), and group 3 (1080 mL).
There were no intraoperative complications. Five major
complications occurred among the entire group (10.6%),
including one bowel obstruction requiring surgery, one
chyle leak resolved with medical therapy, and one mesen-
teric vein bleeding that required re-exploration and liga-
tion. One patient developed renal failure with complete
recovery after undergoing a right nephrectomy with left
renal vein reimplantation for resection of the tumor. The
left renal vein reimplantation was patent on duplex scan.
Finally, one patient developed early graft thrombosis after
complete (four-segment) IVC replacement with a PTFE
graft and reimplantation of hepatic and both renal veins.
The patient developed severe scrotal and bilateral lower
extremity edema. On a postoperative CT scan, the renal
veins and the suprarenal graft replacement remained pat-
ent, with thrombosis of the infrarenal portion of the graft.
The patient was anticoagulated with heparin and dis-
charged on warfarin therapy. A duplex scan at the 3-week
follow-up after discharge showed that a portion of the graft
had recanalized, with complete resolution of the scrotal and
lower extremity edema.
Five additional patients were discharged on warfarin
Fig 2. Cumulative graft patency in patients with inferio
to imaging (last available ends the interval) or imaging
patients entering each interval. Black star indicates standtherapy, two for a history of atrial fibrillation, one for a cistory of pulmonary embolism, and two because of a
istory of DVT. There was no difference in morbidity
etween patients undergoing primary, patch, circumferen-
ial, and extensive reconstruction. No patients presented
ith graft infection, in-hospital DVT, or pulmonary embo-
ism. There were no early deaths.
Follow-up ranged from 1.5 to 216 months (18 years)
ith a mean of 3.5 years. One graft (infrarenal and perire-
al, left renal vein reimplanted) thrombosis occurred at 10
onths during an episode of sepsis and hypotension in a
atient undergoing chemotherapy. The patient was treated
ith warfarin, with resolution of the initial symptoms of
enous hypertension. The patient died 20 months after the
nitial procedure.
CT scans during follow-up were available for review for
8 of 47 patients and for 15 of 27 patients in group 3 at a
ean interval of 36 months and 20 months, respectively.
arrowing of the IVC with continued patency (one in each
roup) occurred secondary to tumor recurrence. Four pa-
ients developed limb edema without evidence of graft
hrombosis or DVT on duplex scan, also associated with
umor recurrence. These patients were treated by their
rimary physicians with warfarin because they were deemed
t risk for DVT. Cumulative 5-year patency for group 3
ased on imaging alone (15 patients) was 80%  10% at 5
ears. Cumulative 5-year patency based on imaging and
linical findings was 92%  5.1% (Fig 2).
Cumulative long-term survival (all-cause mortality by
SDI) for the entire series was 45%  8.5% at 5 years
range, 2 months-17 years; Fig 3). There was no significant
ifference in 5-year cumulative survival between primary
epair and circumferential graft replacement (59% vs 47%,
espectively). Patients with patch repair had worse 5-year
umulative survival, at 27% (Fig 4), although the small
umber of patients in this group does not allow for mean-
ngful statistical analysis (standard error10%). The 5-year
a cava (IVC) resection and graft replacement according
clinical information. Number in parentheses represents
rror 10%.r ven
andumulative survival was similar between single-segment and
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May 20121390 Quinones-Baldrich et alextensive IVC repair (47%  18% vs 52%  13%). Mean
long-term survival was 5.8  0.56 years (range, 2
months-18 years), with a significant difference between
primary or patch (mean, 6.5 years) and circumferential or
Fig 3. Cumulative survival of 47 patient undergoing in
excision. Number in parentheses represents patients ente
Fig 4. Cumulative survival of patients according to typ
primary IVC repair; group 2, patch IVC repair; group 3,
parentheses represents patients entering each interval. Blextensive repair (mean, 4.2 years; P  .005). pThe difference between the cumulative and mean sur-
ival analysis in the comparison of the primary and patch
roup with the graft replacement group is likely the result
f the longest follow-up survivors being in the primary and
vena cava (IVC) resection and repair for en bloc tumor
each interval. Black star indicates standard error 10%.
inferior vena cava (IVC) resection and repair: group 1,
mferential resection with graft replacement. Number in
ar indicates standard error 10%.feriore of
circuatch group. The longest survivor in the graft replacement
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Volume 55, Number 5 Quinones-Baldrich et al 1391group is 8.6 years vs 16.7 and 18 years for two patients in
the patch group. Similar to the cumulative survival analysis,
mean survival did not differ between patients undergoing
single-segment and extensive IVC repair (3.1 vs 3.6 years;
P  .12).
DISCUSSION
IVC resection can be performed safely at the time of
retroperitoneal tumor removal. Reconstruction, regardless
of the extent of IVC resection, was associated with very low
morbidity, low mortality, and had excellent clinical results.
From this experience, it is not possible to establish whether
similar results would follow tumor and IVC resection with
ligation rather than reconstruction. The patient who had an
extensive reconstruction with thrombosis of the IVC graft
below the renal vein reimplantation experienced significant
lower extremity and scrotal edema, suggesting the outcome
of ligation alone. Remarkably, these symptoms resolved
completely within 3 weeks with documented recanalization
of the infrarenal IVC graft on duplex scan. The patient
remains anticoagulated and asymptomatic.
The extent of IVC resection and reconstruction did not
correlate with early morbidity and mortality but did with
overall long-term survival. Patients with more extensive
resections and IVC replacement have the lowest long-term
survival, reflecting more extensive and aggressive tumors.
Quality of survival, however, was likely improved by IVC
reconstruction. In a report by Daylami et al3 after IVC
resection and ligation, 50% of patients developed lower
extremity edema, and 50% developed acute renal failure.
Renal failure resolved, and the authors concluded that this
complication was common and that lower extremity edema
after ligation of the IVC was well tolerated.3 We did not
observe this degree of either complication in our experi-
ence.We agree with others1,5 that routine repair or replace-
ment after circumferential excision of the IVC can be
performed with low morbidity and mortality and is the
preferred approach.
Survival in our series has been better than some,8,9 but
similar to others who have reported extensive and complete
tumor resection with IVC involvement.10,11 Direct com-
parison would not be appropriate given the diversity of
tumors in all series, including ours. In addition, some series
have included patients with hepatic resections combined
with IVC reconstruction.5,12 Positive surgical margins sig-
nificantly affect recurrence and survival.10 In a literature
analysis by Mingoli et al,13,14 patients who underwent
radical resection of leiomyosarcoma of the vena cava had a
significantly better survival at 5 and 10 years. Therefore, an
aggressive approach to complete tumor removal is essential
in the treatment of these malignancies.
Similar to our series, when circumferential replacement
is necessary, the extent of the IVC replacement did not
affect morbidity or survival. In the experience reported
here, there were no significant long-term graft-related
complications. There was a survival difference in favor of
patients who underwent partial IVC resection with primary
or patch repair compared with those who required circum- terential excision. However, long-term survival between
hose who underwent single-segment and extensive IVC
eplacement was similar, suggesting that even large tumors
ith extensive involvement of the IVC are best managed
ith complete resection. Whereas in the past adjuvant
herapy was considered ineffective,14,15 adjuvant chemo-
herapy or radiotherapy, or both, is now considered an
ntegral component of the treatment in these patients.8,10
Some technical aspects of IVC reconstruction deserve
urther emphasis. We prefer to use a ring-supported PTFE
raft for complete replacement and use a diameter smaller
han the IVC (typically, a 12- to 14-mm graft) to promote
aster velocities in the graft segment (Fig 5). We have not
sed adjunctive arteriovenous fistula for any of these recon-
tructions. Partial ring support is maintained at openings
or reimplantation of renal or hepatic veins, as previously
escribed.7 During unclamping, the patient is kept in Tren-
elenburg to remove air from the graft, and the graft is
lled with heparinized saline to avoid an air embolus. When
etrohepatic cava resection is necessary, suprahepatic IVC
ontrol and a Pringle maneuver allows resection and recon-
truction of the retrohepatic cava. A shunt has not been
ecessary even in these extensive repairs.
When right renal vein reimplantation is planned, con-
rol of the right renal artery is recommended to avoid
arenchymal congestion because no collateral drainage ex-
sts for the right renal vein. Arterial control is not necessary
hen left renal vein reimplantation is required, unless the
drenal and gonadal veins have been ligated as part of the
esection. Somewould suggest that left renal vein ligation is
n acceptable alternative as long as these collateral pathways
re present, and that may be the case. Often, however, these
ollateral pathways are affected by the extensive tumor
esection, and we routinely reimplant one or both renal
eins, as indicated.
Intraoperative heparinization is not used routinely and
hould be avoided, particularly for extensive tumor resec-
ions. We limit its use to patients with a history of throm-
otic complications or a finding caval thrombus at opera-
ion. We prefer instead liberal use of heparinized saline.
his may account for the low incidence of postoperative
emorrhage in our series compared with others who advo-
ate intraoperative anticoagulation.1,5 Postoperative anti-
oagulation was not recommended routinely and was only
sed because of a clinical indication such as DVT, pulmo-
ary embolism, and in some cases, limb edema due to
umor recurrence.
One major weakness of this study is the lack of imaging
o document long-term patency of the IVC reconstruction
n all patients. Imaging for this review was available for 28
f the 47 patients at a mean follow-up of 36 months after
he IVC repair. An attempt to obtain a duplex evaluation of
ll surviving patients at of the time of this review was
urtailed by the wide geographic distribution of their cur-
ent location, insurance issues, and other factors. All pa-
ients were seen shortly after discharge by the senior author
W.Q-B.), and routine imaging was not obtained unless
here was a clinical indication.
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The vascular service re-evaluated the patient only when
there was clinical evidence of venous hypertension. Tumor
recurrence caused lower extremity edema in four patients
with patent grafts. The potential clinical benefit of a patent
IVC in these four cases cannot be determined. Two patients
in group 3—the patient with early thrombosis and recana-
lization and a patient who developed sepsis and hypoten-
sion during chemotherapy—had documented graft throm-
bosis, with extensive replacement.
Cumulative 5-year patency for IVC graft replacement,
determined by imaging (80%) and on imaging and clinical
performance (92%), was excellent. We suspect additional
graft failures have occurred over time, allowing the devel-
opment of collateral drainage and thus of little or no clinical
consequence. Even if this is the case, and given no increase
in morbidity and mortality, it argues in favor of IVC recon-
struction at the time of en bloc tumor resection.
CONCLUSIONS
En bloc resection and reconstruction of the IVC can be
performed with very low morbidity and mortality and is
associated with a low incidence of symptoms of venous
hypertension. The extent of the IVC involvement, resec-
tion, and reconstruction correlates with survival, reflecting
more aggressive and extensive tumors. The experience we
have reported here is the largest series of circumferential
Fig 5. A, Magnetic resonance image of 64-year-old m
suprarenal, and retrohepatic inferior vena cava. B, Recon
14-mm polytetrafluoroethylene ringed graft and reimp
performed first, after hepatic vascular isolation and liverresection and replacement of the IVC for en bloc tumoresection, and our results support continuing this aggres-
ive approach in the management of retroperitoneal tumors
ith caval involvement.
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Dr Gregory J. Landry (Portland, Ore). The authors present their
data on inferior vena cava reconstruction during retroperitoneal tumor
resection, an experience of 47 patients over 2 decades. The results are
exemplary, with no perioperative mortality and a complication rate of
only 10%, most of which were transient. This is remarkable given the
extensivenatureof theseprocedures,which typically include severalhours
of surgery by the surgical oncologists in addition to the extensive vascular
reconstruction performed by the consulting vascular surgeon.
The data that Dr Quinones has presented are commendable
and to a certain degree unassailable. These patients have a horrible
problem with few alternatives. When it comes to cancer, typically
you gotta do what you gotta do. Surgical treatment at centers of
excellence such as UCLA is their best and often last hope. Most of
my questions are therefore of a technical and philosophical nature:
1. Do the authors have any information on the functional out-
comes of these patients? Most patients state that they prefer
quality of life over quantity of life. How many patients are able
to return to their preoperative level of function? How many
require placement in skilled nursing facilities? I note in partic-
ular one patient was 89 years old and wonder howmuch benefit
this patient actually received from this procedure.
2. Follow-up data were available on only 30/47, or 64%, of patients.
The lost-to-follow-up group is one with which we struggle in the
vascular literature, yet it is one that is important to try to under-
stand. Was the group that did not follow-up a sicker group with
inferior survival? Alternatively, was this a group that was doing so
well that they did not feel that follow-up was necessary?
3. I found it remarkable that suprarenal and retrohepatic caval cross-
clamping was so well tolerated, with the only intervention neces-
sary being fluid boluses. Do the authors use intraoperative echo-
cardiography to assess volume status, and what is their back-up
strategy if cross-clamping is not tolerated?While shunting was not
necessary in any patient, do the authors have a shunt available at
the time of clamping?
4. The authors recommend autogenous patching when bowel is
resected yet favor a synthetic graft in cases where a portion of
the IVC is replaced. In our own experience with caval recon-
struction, as well as with portal vein reconstruction, we have
typically favored autogenous replacement with femoral vein,
using a panel femoral vein graft if necessary to create an appro-
priate size match. Could the authors comment on the use of
alternate conduits, such as autogenous femoral vein and cryo-
preserved conduit, which is advocated by some?
5. Finally, I was curious how the authors came to the decision to
use a smaller (12-14 mm) graft, with the theoretic advantagedata to indicate that the patency of this would be superior to a
prosthetic graft of equal size to the IVC?
I would like to thank the society for asking me to discuss this
aper as well as Dr Quinones and his associates for forwarding this
aper to me well in advance of the meeting.
Dr William Quinones-Baldrich. I appreciate Dr Landry’s review
f our manuscript. I would like to address the questions in the order
resented:
. We do not have any specific information regarding quality of
life. It would be difficult to collect such data as the timing of the
questioning would have a significant impact on the response.
These patients receive chemo and radiation therapy and, cer-
tainly, inquiring about quality of life during those intervals
would be very different than if they were at a different time in
their recovery. In regard to the 89-year-old patient, he is alive
and well 2 years after the intervention.
. We do have follow-up data on all patients regarding survival.
We do not have follow-up imaging on all patients. I would
suspect that the sicker patients more likely had imaging com-
pared to those that did well. It was often difficult to obtain
imaging follow-up in all in part due to the large region from
where these patients were referred.
. Regarding the tolerance of suprarenal and retrohepatic cava
cross-clamping, it has been our experience that this is well
tolerated provided the patient has adequate volume. We coor-
dinate cross-clamping with the anesthesiologist and so far
shunts have not been necessary. We do not use echocardiogra-
phy routinely during these cases.
. Whereas we would favor portal vein reconstruction with autog-
enous material given its small size, we have found a prosthetic
patch to perform well in vena cava reconstructions. We have
used cryopreserved iliac veins in cases of iliac vein resection, but
this would present a cost concern for vena cava reconstruction
when an alternative is clearly available. We reserve autogenous
reconstruction for cases with potential contamination from
bowel resection. In those instances, we prefer to use internal
jugular vein rather than lower extremity vein to avoid an addi-
tional risk factor for lower extremity edema.
. Regarding the choice of smaller diameter ringed-PTFE grafts for
vena cava replacement, we do not have specific data as to its
superiority over larger-diameter grafts. We do believe that increas-
ing velocity of flow through the replaced segment is a potential
advantage and certainly has worked well in our experience.I want to thank theDr Landry for his excellent questions and the
estern Vascular Society for the opportunity to present our study.
